Innovent Presented Results of IBI302 in P-Ib Clinical Trial for the Treatment of Neovascular Age-Related Macular Degeneration at AAO 2021

Shots:

The P-Ib clinical trial evaluates the safety & tolerability of IBI302 multi-intravitreal injection in 18 patients with nAMD
The results showed an improvement in visual acuity & reduction in retinal edema were observed @4wks. after three loading treatments. The therapy was safe and well-tolerated with no report of dose-limiting toxicity, & no treatment-related serious AEs were observed
IBI302 is a bispecific anti-VEGF & anti-complement recombinant fully human fusion protein which has developed by Innovent. The company to investigate the efficacy of IBI302 on retinal fibrosis and macular atrophy along with visual acuity and retinal thickness improvement in the next study

Click here to read the full press release/ article | Ref: PR Newswire | Image: Fierce Pharma